A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.
Smita Jaggernauth, PharmD
Advertisement
Articles by Smita Jaggernauth, PharmD
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Mutation May Be Associated With Resistance to NSCLC ImmunotherapyNovember 8th 2017
Advertisement
Advertisement
Trending on AJMC
1
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
2
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
3
First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA
4
Endometriosis Reduces Ovarian Reserve via Inflammation and Surgery
5